Douglas Tsao
Stock Analyst at HC Wainwright & Co.
(4.25)
# 410
Out of 5,148 analysts
516
Total ratings
48.18%
Success rate
17.55%
Average return
Main Sectors:
Stocks Rated by Douglas Tsao
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TBPH Theravance Biopharma | Maintains: Buy | $20 → $27 | $18.95 | +42.48% | 17 | Mar 2, 2026 | |
| ARGX argenx SE | Maintains: Buy | $915 → $940 | $756.76 | +24.21% | 42 | Feb 27, 2026 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $30 → $34 | $24.76 | +37.32% | 5 | Feb 26, 2026 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $45 → $48 | $20.70 | +131.88% | 28 | Feb 25, 2026 | |
| OTLK Outlook Therapeutics | Reiterates: Neutral | $0.5 | $0.42 | +18.48% | 20 | Feb 18, 2026 | |
| IMVT Immunovant | Reiterates: Buy | $35 | $27.75 | +26.13% | 24 | Feb 10, 2026 | |
| ROIV Roivant Sciences | Maintains: Buy | $26 → $33 | $28.10 | +17.44% | 23 | Feb 10, 2026 | |
| EOLS Evolus | Maintains: Buy | $20 → $13 | $4.29 | +203.03% | 30 | Feb 3, 2026 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $340 → $1,245 | $330.59 | +276.60% | 31 | Jan 30, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $80 → $117 | $94.24 | +24.15% | 36 | Jan 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $21.28 | +78.57% | 4 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $11 | $11.81 | -6.86% | 17 | Dec 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $5 | $3.14 | +59.24% | 19 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $40 | $28.37 | +40.99% | 3 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $1.61 | +645.34% | 18 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $4 | $6.90 | -42.03% | 15 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $3.30 | +384.85% | 27 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $46 | $30.25 | +52.07% | 25 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $3.28 | +113.41% | 10 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $118 | $66.54 | +77.34% | 16 | Jul 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $81 | $40.68 | +99.12% | 24 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $53 | $42.55 | +24.56% | 5 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $1.65 | +324.24% | 25 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $34 | $30.25 | +12.40% | 16 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $3.20 | +462.50% | 7 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $1.06 | +33,862.26% | 8 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $2.24 | +346.43% | 5 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $168 → $182 | $108.27 | +68.10% | 4 | Feb 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $19 | $8.09 | +131.77% | 2 | Jan 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $25 → $18 | $54.54 | -67.00% | 3 | Aug 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underweight | $8 | $33.77 | -76.31% | 7 | Jun 11, 2019 |
Theravance Biopharma
Mar 2, 2026
Maintains: Buy
Price Target: $20 → $27
Current: $18.95
Upside: +42.48%
argenx SE
Feb 27, 2026
Maintains: Buy
Price Target: $915 → $940
Current: $756.76
Upside: +24.21%
Arcutis Biotherapeutics
Feb 26, 2026
Maintains: Buy
Price Target: $30 → $34
Current: $24.76
Upside: +37.32%
Apellis Pharmaceuticals
Feb 25, 2026
Maintains: Buy
Price Target: $45 → $48
Current: $20.70
Upside: +131.88%
Outlook Therapeutics
Feb 18, 2026
Reiterates: Neutral
Price Target: $0.5
Current: $0.42
Upside: +18.48%
Immunovant
Feb 10, 2026
Reiterates: Buy
Price Target: $35
Current: $27.75
Upside: +26.13%
Roivant Sciences
Feb 10, 2026
Maintains: Buy
Price Target: $26 → $33
Current: $28.10
Upside: +17.44%
Evolus
Feb 3, 2026
Maintains: Buy
Price Target: $20 → $13
Current: $4.29
Upside: +203.03%
Praxis Precision Medicines
Jan 30, 2026
Maintains: Buy
Price Target: $340 → $1,245
Current: $330.59
Upside: +276.60%
Protagonist Therapeutics
Jan 30, 2026
Maintains: Buy
Price Target: $80 → $117
Current: $94.24
Upside: +24.15%
Jan 9, 2026
Reiterates: Buy
Price Target: $38
Current: $21.28
Upside: +78.57%
Dec 26, 2025
Reiterates: Neutral
Price Target: $11
Current: $11.81
Upside: -6.86%
Dec 12, 2025
Maintains: Buy
Price Target: $14 → $5
Current: $3.14
Upside: +59.24%
Dec 9, 2025
Maintains: Buy
Price Target: $34 → $40
Current: $28.37
Upside: +40.99%
Dec 2, 2025
Reiterates: Buy
Price Target: $12
Current: $1.61
Upside: +645.34%
Nov 6, 2025
Maintains: Neutral
Price Target: $5 → $4
Current: $6.90
Upside: -42.03%
Oct 10, 2025
Reiterates: Buy
Price Target: $16
Current: $3.30
Upside: +384.85%
Sep 9, 2025
Reiterates: Neutral
Price Target: $46
Current: $30.25
Upside: +52.07%
Aug 14, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $3.28
Upside: +113.41%
Jul 3, 2025
Reiterates: Buy
Price Target: $118
Current: $66.54
Upside: +77.34%
Jun 27, 2025
Reiterates: Buy
Price Target: $81
Current: $40.68
Upside: +99.12%
May 13, 2025
Reiterates: Buy
Price Target: $53
Current: $42.55
Upside: +24.56%
Apr 29, 2025
Reiterates: Buy
Price Target: $7
Current: $1.65
Upside: +324.24%
Apr 23, 2025
Reiterates: Buy
Price Target: $34
Current: $30.25
Upside: +12.40%
Mar 7, 2025
Reiterates: Buy
Price Target: $18
Current: $3.20
Upside: +462.50%
Oct 1, 2024
Reiterates: Buy
Price Target: $360
Current: $1.06
Upside: +33,862.26%
Jun 7, 2022
Downgrades: Neutral
Price Target: $10
Current: $2.24
Upside: +346.43%
Feb 20, 2020
Maintains: Equal-Weight
Price Target: $168 → $182
Current: $108.27
Upside: +68.10%
Jan 23, 2020
Downgrades: Neutral
Price Target: $19
Current: $8.09
Upside: +131.77%
Aug 29, 2019
Maintains: Underweight
Price Target: $25 → $18
Current: $54.54
Upside: -67.00%
Jun 11, 2019
Initiates: Underweight
Price Target: $8
Current: $33.77
Upside: -76.31%